BIVI BioVie Inc. logo

BIVI BioVie Inc.

Healthcare
$1.44+0.00%OpenMarket Cap: $10.9M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

PEG

P/B

0.73

P/S

0.00

EV/EBITDA

0.07

DCF Value

$12.83

FCF Yield

-178.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-101.1%

ROA

-113.7%

ROIC

-129.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 null$0.00$-5.3M$
Q2 null$0.00$-6.1M$
Q1 null$0.00$-5.1M$
Q4 null$0.00$-3.5M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Sherman Michael Edwarddirector
SellFri Jan 09
Sherman Michael Edwarddirector
SellFri Jan 09
ROGICH SIGMUNDdirector
SellFri Jan 09
ROGICH SIGMUNDdirector
SellFri Jan 09
Palumbo Joseph Mofficer: Chief Medical Officer
SellFri Jan 09

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.72

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Peers